logo
logo
OFIX stock ticker logo

Orthofix Medical Inc.

NASDAQ•OFIX
CEO: Mr. Geoffrey C. Gillespie
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1992-04-24
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Contact Information
3451 Plano Parkway, Lewisville, TX, 75056, United States
214-937-2000
www.orthofix.com
Market Cap
$515.98M
P/E (TTM)
-5.7
30
Dividend Yield
--
52W High
$17.60
52W Low
$10.24
52W Range
38%
Rank38Top 36.9%
4.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$219.91M+0.00%
4-Quarter Trend

EPS

-$0.06+0.00%
4-Quarter Trend

FCF

$7.12M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Sales Growth Achieved Total net sales reached $822.3M, reporting 2.9% growth; constant currency growth was 2.4% for the year.
Gross Margin Expansion Gross Margin improved 0.5 points to 68.8%; Net Loss narrowed by $33.8M compared to the prior year results.
Limb Reconstruction Sales Rise Global Limb Reconstruction sales increased 8.4% reported to $134.7M; U.S. growth led at 15.8% driven by investments.
R&D Spending Reduced Research and development expense decreased 10.6% to $65.8M following strategic discontinuation of M6 product lines.

Risk Factors

Healthcare Industry Consolidation Industry consolidation pressures pricing; GPOs/IDNs may exclude suppliers, materially affecting profitability and market access.
Integration of SeaSpine Merger Continued SeaSpine integration poses risk; failure to achieve intended synergies may adversely affect operating efficiencies and cost savings goals.
Pending Litigation Exposure Multiple litigation and arbitration matters pending, including former executives; accrual of $18.3M reflects ongoing financial uncertainty.
Regulatory Compliance Costs Extensive global regulation, especially E.U. MDR, requires significant ongoing costs to maintain compliance and market access.

Outlook

Focus on Profitable Growth Discontinuing M6 product lines to allocate resources toward more profitable growth opportunities across Global Spine segment.
Digital Platform Leverage Limb Reconstruction strategy emphasizes leveraging OrthoNext digital platform for planning and improving surgical outcomes.
Spine Technology Development Future growth driven by internally developed technologies and external acquisitions, focusing on cervical and thoracolumbar anatomy.
Liquidity Management Intend to retain consolidated earnings to finance continued growth; currently compliant with $15.0M unrestricted cash covenant.

Peer Comparison

Revenue (TTM)

VREX stock ticker logoVREX
$854.40M
+4.1%
OFIX stock ticker logoOFIX
$822.31M
+2.9%
AVNS stock ticker logoAVNS
$701.20M
+1.9%

Gross Margin (Latest Quarter)

ABSI stock ticker logoABSI
100.0%
+197.2pp
KALV stock ticker logoKALV
91.0%
+0.0pp
LAB stock ticker logoLAB
83.5%
-3.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MLTX$1.25B-5.0-67.1%17.8%
SVRA$1.14B-10.4-86.6%21.2%
BFLY$929.58M-12.1-35.3%6.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.3%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:May 4, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data